Q-BEAM · SURGICAL COMMAND CENTER

Every second
saves a life.

Quantum-optimized laser trajectory planning for brain tumor ablation. From scan to plan, in seconds — not hours.

THE PROBLEM

LITT planning is stuck in the past.

0%

MALIGNANT BRAIN TUMORS

Of all malignant brain and CNS tumors are Glioblastoma — the most aggressive primary brain cancer.

0%

TURNED AWAY FROM LITT

Patients are denied laser interstitial thermal therapy due to complex tumor shape and size — an access crisis.

0%

REQUIRE MULTIPLE PROBES

Even accepted patients need multiple laser probes to achieve adequate ablation. Today's planning can't optimize for one-shot coverage.

01 · PERCEPTION

The brain, segmented.

Swin UNETR transforms multi-modal MRI into a 3D map of tumor, critical structures, and healthy tissue.

TUMOR · SEGMENTED

02 · PHYSICS

Heat, predicted.

Pennes' bioheat equation models thermal diffusion in 3D — every voxel, every watt, every millisecond.

PENNES · BIOHEAT

03 · OPTIMIZATION

Optimal, not approximate.

Trajectory planning formulated as a QUBO and solved on the D-Wave Advantage2 quantum annealer in seconds.

QUBO · SOLVED

SEE IT IN MOTION

From scan to plan, in seconds.

WHY QUANTUM

Trajectory planning is a combinatorial problem.

  • High-dimensional, non-convex search space with thousands of candidate trajectories.
  • Classical solvers get stuck in local minima — every run can produce a different "acceptable" plan.
  • Quantum sampling on D-Wave Advantage2 finds the global minimum in seconds.

FAU hosts Florida’s first onsite quantum computer — we run Q-Beam there.

TRACTION

Validated by the people who know.

WINNERS

FAU 2026 Biotech Hackathon

$1,500 first prize

WINNERS

FAU Business Pitch

$2,500 first prize

ACCEPTED

FAU Tech Runway

~$100k in non-dilutive accelerator resources

SELECTED

Florida Governor's Cup

Upcoming statewide finalist — 2026

ADVISORS & PARTNERS

Backed by the people building the frontier.

QUANTUM HARDWARE

D-Wave Quantum

ACADEMIC

FAU Quantum Research

CLINICAL RESEARCH

Advanced Research LLC

EARLY ACCESS

Be first in line.

Clinical partners and investors — drop your email. We’ll reach out when we open the next cohort.